Verona Pharma

206 articles about Verona Pharma

• Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine

  6/25/2019

  Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team.

• Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

  6/4/2019

  Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2 dose-ranging trial to evaluate the pharmacokinetic (“PK”) profile, efficacy and safety of a pressurized metered-dose inhaler (“MDI”) formulation of ensifentrine (RPL554) in patients with moderate-to-severe chronic obstructive pulmonary disease

• 

  BioSpace's Global Biopharma Roundup: March 7

  3/7/2019

  Biotech and pharma companies from across the globe share data and news in a weekly roundup.

• Reminder: Ligand to Host Analyst Day on March 12th in New York City

  2/21/2019

  Event to feature business updates and presentations by four corporate partners

• 

  BioSpace Movers and Shakers: Jan. 4

  1/4/2019

  Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.

• Verona Pharma: PDMR Dealing

  11/30/2017

  The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

• Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

  11/7/2017

  Top-line data from the study now expected in mid-2018.

• Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

  11/7/2017

  Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD.

• Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

  10/31/2017

  The company will host an investment community conference call at 8:00 a.m. ET on November 7, 2017 to discuss the results.

• Verona Pharma Reports Positive Top-Line Data From U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose To Patients

  9/27/2017

• Verona Pharma Announces Positive Top-Line Data From Phase IIa Clinical Trial In COPD With RPL554 Dosed In Addition To Tiotropium (Spiriva)

  9/7/2017

• Verona Pharma Release: PDMR Dealing

  8/21/2017

• Verona Pharma Interim Results For The Six Months Ended June 30, 2017 And Clinical Development Update

  8/8/2017

• Verona Pharma To Announce Interim Results For Six Months Ended June 30, 2017 And Provide Clinical Development Update

  8/2/2017

• Verona Pharma Doses First Patients In Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment

  7/26/2017

• Verona Pharma Receives Regulatory Approval To Commence Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment In Five Countries Across Europe

  6/26/2017

• Verona Pharma Appoints Dr. Desiree Luthman As Vice President Of Regulatory Affairs

  6/22/2017

• Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study For RPL554 Following Acceptance Of IND Application By FDA

  6/5/2017

• Verona Pharma Announces Closing Of Exercise Of Underwriters’ Over-Allotment Option

  5/19/2017

• Verona Pharma Release: Grant Of Options And RSUs And PDMR Dealings

  5/3/2017